About the Project
This four year PhD project aims to characterise and understand the biological significance of MCT1 subcellular localisation for cancer cell metabolism, progression and treatment outcome. To achieve this, endometrial cancer cell lines with MCT1 knock-down or with only nMCT1 or PM MCT1 expression will be engineered using CRISPR-CAS9 technology and will be subjected to functional assays measuring metabolic activity (MTT, Seahorse), proliferation (SRB, ki67, cell cycle analysis) and progression (migration/invasion). Further, the engineered cell lines will be characterised for their sensitivity to different chemotherapeutic agents and will be used to understand the impact of MCT1 subcellular localisation on treatment and patient outcome. Also, the potential of these chemotherapeutic agents on MCT1 expression or translocation will be evaluated. Additionally, the role of nMCT1 will be further characterised by identifying binding partners of nMCT1 using co-immunoprecipitation and by identifying alterations in gene expression in engineered cell lines. Information gathered from these experiments may identify novel targets that influence and/or are influenced by MCT1 subcellular localisation which may prove useful in cancer therapy.
Candidates are expected to hold (or be about to obtain) a minimum upper second class honours degree (or equivalent) in a related area/subject. Candidates with a master’s degree in a related area/subject, and experience in molecular biology and/or gene editing (CRISPR) are encouraged to apply. Informal enquiries may be made directly to the primary supervisor. On the online application form select PhD Molecular Biology or Cancer Sciences.
For international students we also offer a unique 4 year PhD programme that gives you the opportunity to undertake an accredited Teaching Certificate whilst carrying out an independent research project across a range of biological, medical and health sciences. For more information please visit http://www.internationalphd.manchester.ac.uk
Equality, diversity and inclusion is fundamental to the success of The University of Manchester, and is at the heart of all of our activities. The full Equality, diversity and inclusion statement can be found on the website View Website
2. deOliveira et al., 2012. Co-expression of monocarboxylate transporter 1 (MCT1) and its chaperone (CD147) is associated with low survival in patients with gastrointestinal stromal tumors (GISTs). J Bioenerg Biomembr. 2012;44:171–8.
3. Eilertsen et al., 2014. Monocarboxylate transporters 1-4 in NSCLC: MCT1 is an independent prognostic marker for survival. PLoS One. 2014;9:e105038.
4. Latif et al., 2017. Monocarboxylate Transporter 1 (MCT1) is an independent prognostic biomarker in endometrial cancer. BMC Clinical Pathology (2017) 17:27
5. Pinherio et al., 2014. Characterization of monocarboxylate transporters (MCTs) expression in soft tissue sarcomas: distinct prognostic impact of MCT1 subcellular localization. J Transl Med. 2014;12:118.
Why not add a message here
Based on your current searches we recommend the following search filters.
Based on your current search criteria we thought you might be interested in these.